Reduced expression of circRNA hsa_circ_0067582 in human gastric cancer and its potential diagnostic values

Abstract

Background Gastric cancer (GC) is one of the global mortality diseases and has a poor prognosis due to the lack of ideal tumor biomarkers. Circular RNAs (circRNAs) are an abundant kind of endogenous RNAs that recently are found play a crucial role in the cancer occurrence and development. Nevertheless, little is known with regard to the diagnostic values of these circRNAs for GC. In this article of research, we investigated the role of hsa_circ_0067582 in clinical diagnosis of GC. Materials and Methods We used divergent primers, and the expression levels of hsa_circ_0067582 in 93 fresh GC tissues and paired adjacent normal tissues from surgical patients were detected using quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR). Then, a receiver operating characteristic (ROC) curve was established to assess the diagnostic significance of hsa_circ_0067582. The relationship between expression of hsa_circ_0067582 and clinicopathological factors of patients was made further explored. Results Hsa_circ_0067582 levels were significantly decreased in GC tissues contrasted with adjacent normal tissues (n = 93, P < .001). After that, we discovered that it was evidently downregulated in 81.7% (76/93) GC tissues. The area under the ROC curve (AUC) of hsa_circ_0067582 was up to 0.6937, the sensitivity was 66.67%, and the specificity was 61.29%. Moreover, the hsa_circ_0067582 levels were obviously associated with tumor diameter (P = .002) and carbohydrate antigen 19‐9 (CA19‐9, P = .01). Meanwhile, after operation, low‐level group of hsa_circ_0067582 of GC patients was associated with better prognosis. Conclusion Our data imply that hsa_circ_000067582 may be a potential biomarker for GC diagnosis and prognosis evaluation.

CircHN1 affects cell proliferation and migration in gastric cancer

“…The roles of circRNAs in cancer biology have attracted wide attention 16 . Recent studies have demonstrated that some circRNAs are abnormally expressed in GC and involved in the development and progression of GC 17‐20 . CircNRIP1 promotes GC progression by sponging miR‐149‐5p and regulating the AKT1/mTOR pathway 17 .…”

“…CircFAT1(e2) prevents the development of GC by targeting miR‐548g in the cytoplasm and interacting with the YBX1 protein in the nucleus 18 . The expression level of hsa_circ_0067582 is significantly downregulated in GC tissues 19 . Furthermore, hsa_circ_0000419 is lowly expressed in both GC tissues and plasma samples, making it a potential biomarker in GC screening and predictor of patient prognosis 20 .…”

Circular RNAs: Emerging Role in Cancer Diagnostics and Therapeutics

“…GC patients with decreased circ_0005556 levels had a shorter OS than those with higher levels . Circ_0067582 was downregulated in GC tissues and is correlated with increased tumor diameter and high CA19-9 (Yu et al, 2020). Circ_0067582 downregulation was associated with a better prognosis after surgery (Yu et al, 2020).…”

“…Circ_0067582 was downregulated in GC tissues and is correlated with increased tumor diameter and high CA19-9 (Yu et al, 2020). Circ_0067582 downregulation was associated with a better prognosis after surgery (Yu et al, 2020). Circ_0000467 was overexpressed in GC tissue and plasma and this was correlated with the TNM stage (Lu et al, 2019b).…”

<p>CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1</p>

“…In recent years, circular RNAs (circRNAs) are very important in the occurrence and development of tumor and expected to become a biomarker and diagnosis target for tumor treatment. [5][6][7] Predecessors have confirmed that circRNAs are associated with the occurrence, development, and drug resistance of human diseases, such as Alzheimer's disease, hepatocellular carcinoma, lung cancer, breast cancer, and PC. [8][9][10][11][12] Previous studies have shown that circHIPK3 spongs miR-145-5p, miR-124, miR-558, miR-637, miR-193a, miR-338-3p, and miR-637 to regulate oxaliplatin-resistance, proliferation, tube formation, invasion, autophagy, migration, and apoptosis in lung cancer, preeclampsia, gastric cancer, colorectal cancer, chronic myeloid leukemia, bladder cancer, prostate cancer.…”